Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NCT01644669 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radiation treatment in breast conserving therapy in women with early stage breast cancer.

Interventions

  • RADIATION Intra-operative Radiation Therapy - IORT

Study Locations (20)

California

  • City of Hope — Duarte
  • Long Beach Memorial Medical Center — Long Beach
  • UCLA — Los Angeles
  • Tri-City Medical Center — Oceanside
  • Diablo Valley Oncology Hematology Medical Group — Pleasant Hill

Florida

  • Florida Hospital Celebration Health — Celebration
  • Doctors Hospital — Coral Gables
  • Martin Health System Center for Clinical Research — Stuart

Maryland

  • Greater Baltimore Medical Center — Baltimore
  • MedStar Oncology Network - Good Samaritan Hospital — Baltimore
  • MedStar Oncology Network - Franklin Square — Baltimore

Colorado

  • Western Surgical Care, PC — Denver
  • Swedish Medical Center — Englewood

Arizona

  • University of Arizona — Tucson

Illinois

  • Rush University — Chicago

Indiana

  • Lutheran Hospital of Indiana — Fort Wayne

New Hampshire

  • Exeter Hospital — Exeter

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2012-05-08
Est. Completion 2029-12-31
Phase NA

Sponsor

Xoft

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01644669

The ClinicalTrials.gov registry entry for NCT01644669 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoft, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Ductal Carcinoma in Situ appearing as the primary indexed condition, and to 1 intervention — of which Intra-operative Radiation Therapy - IORT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01644669 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01644669 about?

NCT01644669 is a clinical study titled "Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®". The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radi...

What is the current status of trial NCT01644669?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,200 participants. The study started on 2012-05-08. Estimated completion is 2029-12-31.

What conditions does trial NCT01644669 study?

This clinical trial studies the following conditions: Ductal Carcinoma in Situ, Invasive Ductal Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01644669?

The interventions under investigation include: Intra-operative Radiation Therapy - IORT (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01644669?

This trial is sponsored by Xoft, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01644669 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial